These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21949640)

  • 1. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.
    Salzman J; Marinelli RJ; Wang PL; Green AE; Nielsen JS; Nelson BH; Drescher CW; Brown PO
    PLoS Biol; 2011 Sep; 9(9):e1001156. PubMed ID: 21949640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.
    Micci F; Panagopoulos I; Thorsen J; Davidson B; Tropé CG; Heim S
    PLoS Biol; 2014 Feb; 12(2):e1001784. PubMed ID: 24504521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of DPP9 in gene fusions in serous ovarian carcinoma.
    Smebye ML; Agostini A; Johannessen B; Thorsen J; Davidson B; Tropé CG; Heim S; Skotheim RI; Micci F
    BMC Cancer; 2017 Sep; 17(1):642. PubMed ID: 28893231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
    Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
    Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
    Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
    Elattar A; Warburton KG; Mukhopadhyay A; Freer RM; Shaheen F; Cross P; Plummer ER; Robson CN; Edmondson RJ
    Gynecol Oncol; 2012 Jan; 124(1):142-7. PubMed ID: 22001143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
    Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
    J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas.
    Agostini A; Brunetti M; Davidson B; Göran Tropé C; Heim S; Panagopoulos I; Micci F
    Int J Cancer; 2018 Sep; 143(6):1379-1387. PubMed ID: 29633253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survival.
    Sankaranarayanan P; Schomay TE; Aiello KA; Alter O
    PLoS One; 2015; 10(4):e0121396. PubMed ID: 25875127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
    Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
    BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
    Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
    Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer.
    Newtson A; Reyes H; Devor EJ; Goodheart MJ; Bosquet JG
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.